• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Is There an Association between Maternal Corticosteroid Treatment and Behavior Disorders in Offspring?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Räikkönen et al. (JAMA, 2020) investigated whether antenatal corticosteroid treatment is associated with mental and behavioral disorders in children born at term and preterm
  • Gyamfi-Bannerman et al. (JAMA, 2020) provide a ‘Comment and Response’ that provides a review and highlight important clinical points (see below)

METHODS:

  • Population retrospective cohort study
    • Data collected on deliveries ≥22 weeks and ≥500g
  • Participants
    • All singleton live births in Finland surviving until 1 year (2006 through 2017)
  • Exposures
    • Maternal antenatal corticosteroid treatment
    • Number and timing of treatments were not available in the database
  • Finnish corticosteroid protocol
    • Betamethasone (12 mg) twice 24 hours apart
      • Until 2009: up to 34w0d
      • After 2009: Up to 34w6d and possibly later depending on clinical scenario
    • Repeat treatments
      • Until 2009: Not recommended
      • After 2009: 1 repeat course if risk of RDS high
  • Within-sibpair comparison conducted to help address unmeasured familial confounding
    • Sibpairs discordant for treatment exposure were compared with sibpairs concordant for nonexposure
    • Multiple other potential confounders (e.g., maternal age, gestational age, mode of delivery, BMI etc.) were extracted from the database
  • Primary outcome
    • Any childhood mental and behavioral disorder diagnosed in a specialized medical care setting

RESULTS:

  • Total of 670,097 singleton births used in the analysis
    • Median length of follow-up: 5.8 (IQR 3.1-8.7) years
  • Corticosteroid exposure and birth
    • Corticosteroid exposed children: 2.22% | 46.1% female
      • Born at term: 45.27%
      • Born preterm: 54.74%
    • Non-exposed children: 97.78% | 48.9% female
      • Born at term: 96.88%
      • Born preterm: 3.12%
  • Eligible sibpairs: 241,621
    • Discordant for treatment exposure: 1.71%

Compared to non-exposure, exposure to corticosteroids was significantly associated with higher risk of any mental or behavioral disorder

  • Entire cohort
    • Exposed: 12.01%
    • Non-exposed: 6.45%
    • Absolute difference 5.56% (95% CI, 5.04% to 6.19%)
    • Adjusted hazard ratio (HR) 1.33 (1.26 to 1.4)
  • Term-born children
    • Exposed: 8.89%
    • Non-exposed: 6.31%
    • Absolute difference 2.58% (95% CI, 1.92% to 3.29%)
    • HR 1.47 (95% CI, 1.36 to 1.69)
  • Term within-sibpair analysis
    • Exposure in sibling of discordant sibpair was associated with increased risk for mental and behavioral disorder
      • Exposed:6.56%
      • Unexposed: 4.17%
      • Absolute difference: 2.40% (95% CI, 1.67%-3.21%)
      • HR 1.38: (95% CI, 1.21-1.58)
  • Preterm-born children
    • Cumulative incidence was significantly different but not the HR
      • Exposed: 14.59%
      • Non-exposed: 10.71%
      • Absolute difference 3.38% (95% CI, 2.95% to 4.87%)
      • HR 1.00 (95% CI, 0.92 to 1.09)

CONCLUSION:

  • This study identified an association between antenatal exposure to corticosteroids for lung maturity and mental and behavioral disorders in offspring
  • The authors acknowledge multiple limitations, including
    • The data reflecting association and not causation
    • The Finnish population is homogeneous and therefore results may not be generalizable to other populations
  • The authors conclude

…exposure to maternal antenatal corticosteroid treatment was significantly associated with mental and behavioral disorders in children

These findings may help inform decisions about maternal antenatal corticosteroid treatment

Comment and Response from Gyamfi-Bannerman et al. (JAMA, 2020)

The authors, who were all involved with the MFMU RCTs related to corticosteroids use, point out significant limitations with this study, including  

  • Study design
    • Observational study can only assess associations and not causation
  • Absence of key data
    • Number of doses
    • Courses of corticosteroids
    • Gestational age  
    • Indication for corticosteroid administration | Critical as outcome may be related to indication and not medication especially when assessing neurodevelopment
    • Individual-level data on deaths after infancy | Neonatal death is impacted by corticosteroids
    • Gestational age not studied separately in this study | However, the authors also speculate regarding risk of use in the late preterm period
  • Current evidence for corticosteroid use and outcomes
    • Long-term neurodevelopment after a single course of corticosteroids: Data from “well-conducted clinical trials in which patients were randomized” and “dosing and indication for administration were characterized precisely” have been reassuring
    • Late Preterm: Corticosteroids reduce RDS in late preterm neonates | Due to patient volume (late preterm neonates account for the majority of NICU admissions for respiratory disease) | Therefore, use of corticosteroids can prevent a significant proportion of bronchopulmonary dysplasia
  • The authors of this ‘Comment and Response’ conclude

We do not agree that the study supports a reconsideration of the use of antenatal corticosteroids

We agree that clinical care would be improved by devising better ways to accurately select women who actually deliver in the week following administration, but this applies regardless of gestational age

We concur that perinatal trials should evolve to consistently include assessments of long-term outcome

Learn More – Primary Sources:

Associations Between Maternal Antenatal Corticosteroid Treatment and Mental and Behavioral Disorders in Children (Räikkönen et al. JAMA, 2020)

Maternal Antenatal Corticosteroid Treatment and Childhood Mental and Behavioral Disorders (Gyamfi–Bannerman et al. JAMA, 2020)

MFMU Network: Antenatal Betamethasone for Women at Risk for Late Preterm Delivery (NEJM, 2016)

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Antenatal Corticosteroids – When to Administer?
Results from the PRECISE Study: Repeat Prenatal Corticosteroid Treatment for Preterm Birth
Are Topical Corticosteroids Safe During Pregnancy? 
In Women at Risk of Late Preterm Delivery, is Corticosteroid Therapy Still Cost-Effective?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site